烂漫的碧萱
Lv31
390 积分
2022-12-08 加入
-
Gynecological carcinosarcomas: Overview and future perspectives
55分钟前
求助中
-
Reversible HER2 antibody-drug conjugate-induced ocular toxicity
23天前
已完结
-
乳腺癌HER2低表达病理检测进展及挑战
1个月前
已完结
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
1个月前
已关闭
-
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
2个月前
已完结
-
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
3个月前
已完结
-
中国晚期乳腺癌规范诊疗指南(2022版)
3个月前
已完结
-
中国乳腺癌抗体药物偶联物安全性管理专家共识
4个月前
已完结
-
患者报告结局测量工具在乳腺癌患者中的应用进展
4个月前
已完结
-
[Cancer incidence and mortality in China, 2022]
5个月前
已完结